VEGFA and neoplasm: Bevacizumab, a monoclonal antibody, inhibits angiogenesis and tumor growth by targeting anti-vascular endothelial growth factor (VEGF) (Boige et al., 2012; Ferrara et al., 2005; Finn et al., 2009; Siegel et al., 2008).